MICROLITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MICROLITE (MICROLITE).
MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.
| Metabolism | Not metabolized; excreted unchanged by kidneys. |
| Excretion | Renal excretion accounts for approximately 70% of the dose, primarily as unchanged drug. Fecal elimination constitutes about 30%, with a minor contribution from biliary excretion (<10%). |
| Half-life | Terminal elimination half-life is 12–15 hours in healthy adults, allowing twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases). |
| Protein binding | 98% bound to serum albumin. Minimal binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15–0.20 L/kg, indicating distribution primarily into extracellular fluid. Does not extensively penetrate tissues or cross the blood-brain barrier significantly. |
| Bioavailability | Oral: 90% (well absorbed, minimal first-pass metabolism). Intramuscular: 100% (complete absorption). |
| Onset of Action | Oral administration: 30–60 minutes to achieve therapeutic plasma concentrations. Intravenous: immediate (within 5 minutes). |
| Duration of Action | Duration of clinical effect is 8–12 hours after oral dosing, corresponding to receptor occupancy. Sustained release formulations may extend to 24 hours. |
1 tablet orally every 8 hours with or without food.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: 1 tablet every 12 hours; GFR 15-29 mL/min: 1 tablet every 24 hours; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 1 tablet every 12 hours; Child-Pugh C: contraindicated. |
| Pediatric use | Weight <30 kg: 10 mg/kg/dose orally every 8 hours; Weight ≥30 kg: same as adult dosing. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and adjust per renal adjustment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MICROLITE (MICROLITE).
| Breastfeeding | Magnesium is excreted into breast milk; however, oral magnesium citrate is poorly absorbed. Infant exposure is likely minimal. M/P ratio not established. Use caution with high doses as diarrhea in mother may occur, but breastfeeding is generally considered compatible. |
| Teratogenic Risk | MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No specific data but theoretical risk minimal due to poor oral absorption. Second/Third trimester: No known adverse fetal effects; used therapeutically for preeclampsia prevention at higher doses (IV magnesium sulfate, not this oral form). |
■ FDA Black Box Warning
None
| Serious Effects |
Hyperkalemia, hypermagnesemia, severe renal impairment.
| Precautions | Use with caution in renal impairment; monitor serum electrolytes; avoid in patients with hyperkalemia or hypermagnesemia. |
Loading safety data…
| Fetal Monitoring | Monitor serum magnesium levels if high doses used or renal impairment. Assess for maternal signs of hypermagnesemia: hypotension, areflexia, respiratory depression. Fetal monitoring not required for standard oral doses. |
| Fertility Effects | No known negative effects on fertility. Magnesium is essential for normal reproductive function; supplementation may be beneficial in deficiency states. |